A Commentary on the Use of Epstein-Barr Virus Specific Antibodies as Biological Markers in Multiple SclerosisMassimiliano Castellazzi1*, Maura Pugliatti1, Enrico Granieri1 and Enrico Fainardi2
- Corresponding Author:
- Massimiliano Castellazzi
Laboratory of Neurochemistry and Neuroimmunology
University of Ferrara, Via Aldo Moro
8 I-44124 Cona, Ferrara, Italy
E-mail: [email protected]
Received date: March 23, 2017; Accepted date: May 31, 2017; Published date: June 07, 2017
Citation: Castellazzi M, Pugliatti M, Granieri E, Fainardi E (2017) A Commentary on the Use of Epstein-Barr Virus Specific Antibodies as Biological Markers in Multiple Sclerosis. J Neurol Neurophysiol 8:428. doi:10.4172/2155-9562.1000428
Copyright: © 2017 Castellazzi M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Multiple sclerosis (MS), a chronic demyelinating and neurodegenerative disease of the central nervous system (CNS), whose pathogenesis likely involves an interaction of environmental factors with a genetic predisposition. The hypothesis that Epstein-Barr virus (EBV), a ubiquitous human γ-herpesvirus may be a causal agent pivots on the evidence of EBV-specific antibodies high titers in MS patients as compared to controls, and on the observed direct association between such antibodies titers and disease activity. However, the literature on the possible etiological role of EBV is conflicting. This commentary aims to provide an overview on the use of EBV-specific antibodies as biomarkers in MS course.